In January 2007, Dov licensed the rights to bicifadine to XTL Biopharmaceuticals after bicifadine failed in a Phase III clinical trial for chronic lower back pain. XTL ran a PhaseIIb clinical trial for pain caused by diabetic neuropathy, which failed in 2008; XTL terminated the agreement in 2010. In 2010 Dov was acquired by Euthymics Bioscience which intended to continue development of other candidates from Dov's portfolio.
^Wang, R. I.; Johnson, R. P.; Lee, J. C.; Waite, E. M. (1982). "The Oral Analgesic Efficacy of Bicifadine Hydrochloride in Postoperative Pain". Journal of Clinical Pharmacology. 22 (4): 160–164. doi:10.1002/j.1552-4604.1982.tb02157.x. PMID7096604.
^Basile, A.; Janowsky, A.; Golembiowska, K.; Kowalska, M.; Tam, E.; Benveniste, M.; Popik, P.; Nikiforuk, A.; Krawczyk, M.; Nowak, G.; Krieter, P. A.; Lippa, A. S.; Skolnick, P.; Koustova, E. (2007). "Characterization of the Antinociceptive Actions of Bicifadine in Models of Acute, Persistent, and Chronic Pain". The Journal of Pharmacology and Experimental Therapeutics. 321 (3): 1208–1225. doi:10.1124/jpet.106.116483. PMID17325229.